PMID: 9187691Jun 1, 1997Paper

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

Urology
M F DarsonD G Bostwick

Abstract

We describe the expression of a potentially new tumor marker, human glandular kallikrein 2 (hK2), that may be useful as an adjunct to prostate-specific antigen (PSA) in the diagnosis and monitoring of prostate cancer. We evaluated 257 radical prostatectomy specimens removed at the Mayo Clinic with pathologic Stage 12 adenocarcinoma to compare the cytoplasmic expression of hK2, PSA, and prostatic acid phosphatase (PAP) in benign tissue, high-grade prostatic intraepithelial neoplasia (PIN), and adenocarcinoma. Two monoclonal antibodies, hK2-A523 and hK2-G586, specific for hK2 were used, as well as antibodies against PSA (PSM-773) and PAP (polyclonal). Intense epithelial cytoplasmic immunoreactivity was observed in every case for hK2-A523, hK2-G586, PSA, and PAP (100% of cases, respectively). The intensity and extent of hK2 expression for both antibodies were greater in cancer than high-grade PIN; furthermore, high-grade PIN was greater than benign epithelium. Cases of Gleason primary grade 4 and 5 cancer showed hK2 staining in almost every cell, whereas there was greater heterogeneity of staining in lower grades of cancer. In marked contrast to hK2, PSA and PAP immunoreactivity was most intense in benign epithelium and stained to...Continue Reading

Associated Clinical Trials

References

Jan 1, 1994·Mayo Clinic Proceedings·H C RuckleJ E Oesterling
Aug 1, 1996·The Prostate·D G BostwickA Lopez-Beltran

❮ Previous
Next ❯

Citations

Apr 21, 1999·International Journal of Cancer. Journal International Du Cancer·S D MikolajczykM S Saedi
Feb 11, 2005·Journal of Molecular Histology·Paul T JubinskyMaomi Li
Mar 9, 2004·Clinical Biochemistry·Eleftherios P DiamandisA Yvonne Olsson
Nov 7, 2000·Molecular and Cellular Endocrinology·S H MitchellC Y Young
Sep 24, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·G FrenetteJ Y Dubé
Feb 17, 2000·Trends in Endocrinology and Metabolism : TEM·E P DiamandisC V Obiezu
Aug 28, 2013·Journal of Proteome Research·Akos VégváriGyörgy Marko-Varga
Nov 2, 2004·Nature Reviews. Cancer·Carla A Borgoño, Eleftherios P Diamandis
Nov 14, 2007·Prostate Cancer and Prostatic Diseases·K BensalahS F Shariat
Jun 6, 2002·European Journal of Biochemistry·Sylvain M CloutierDavid Deperthes
Jan 20, 2004·European Journal of Biochemistry·Sylvain M CloutierDavid Deperthes
Mar 8, 2002·Environmental Health Perspectives·Edward R SauterEleftherios P Diamandis
Jun 28, 2006·Biological Chemistry·Constantina D PetrakiEleftherios P Diamandis
Jul 17, 2008·Biological Chemistry·Hannu KoistinenUlf-Håkan Stenman
Nov 6, 1998·Clinical Chemistry and Laboratory Medicine : CCLM·R Daher, M Beaini
Jul 31, 2007·Future Oncology·Shahrokh F ShariatClaus G Roehrborn
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·R E ReiterO N Witte
Jul 23, 2014·Medical Oncology·Amrallah A Mohammed
Apr 25, 2006·Virchows Archiv : an International Journal of Pathology·Rodolfo MontironiAldo V Bono

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.